LB Pharmaceuticals Common Stock
LBRX | NASDAQ
$42.13
-$0.86 (-2.00%)
Sep 22, 2026, 10:23 AM ET · Market open
Company Profile
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Key Executives
| Name | Position |
|---|---|
| Heather D. Turner | Chief Executive Officer & Director |
| Anna Eramo | Advisor |
| Christopher Zergebel | Senior Vice President of Clinical Operations |
| Ellen Rose | Senior Vice President of Corporate Affairs |
| James Rawls | Senior Vice President of Regulatory Affairs |
| Kaya Pai Panandiker | Chief Commercial Officer |
| Lindsay Beaupre | Senior VP of People & Culture |
| Marc L. Panoff | Senior Vice President of Finance |
| Minako Pazdera | General Counsel |
| Richard Silva | Senior Vice President of Technical Operations |
| Soffer | Chief Operating & Business Officer |
LB Pharmaceuticals Common Stock
| Country | United States |
| IPO Date | Sep 10, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Heather D. Turner |
Contact Details
One Pennsylvania Plaza New York,
New York 10119 United States
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001691082 |
| CUSIP Number | 50180M108 |
| ISIN Number | US50180M1080 |
| SIC Code | n/a |
Recent News
- 4 days ago / seekingalpha.comLB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity
- 7 days ago / globenewswire.comLB Pharmaceuticals Appoints Susan G. Kozauer, M.D.
- 19 days ago / globenewswire.comLB Pharmaceuticals to Participate in Upcoming September Investor Events
- 2 months ago / globenewswire.comLB Pharmaceuticals Announces $150 Million Private Placement
Add to Watchlist
Select watchlists to add or remove LBRX